Openbookopenbook
Equity
TSHA
+0.0 · +0.00%
USD · NASDAQ

Taysha Gene Therapies Inc(TSHA) Stock Analysis | Healthcare

USD --+0.00%
Reward51Moderate
Risk49Moderate
75%Data
Revenue growing 171% YoY
Profitless Growth
Market Cap:1.88Bn
ⓘ
Reward Rating
51
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
49
Moderate
Risk Assessment
5 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on TSHA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for TSHA, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $13.33.

What is Taysha Gene Therapies Inc?

, a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.

TSHA · Verdict

Moderate reward · moderate risk

TSHA's standout is balance sheet; cash flow and profitability weigh on the picture.

Based on 88% data coverage

TSHA · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet76/100

    Current ratio 12.23

Watchouts 2

  • Cash flow6/100

    -960% free-cash-flow margin

  • Profitability32/100

    -1115% net margin · -47% ROE

Model-based scoring. For information only — not financial advice.

What is Taysha Gene Therapies Inc?

, a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.88B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (51)

The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

KARDSmall Cap / 1.9B market cap
Kardigan, Inc. Common Stock
Compare
IMCRSmall Cap / 1.9B market cap
Immunocore Holdings Ltd
Compare
BRVESmall Cap / 1.9B market cap
Braveheart Bio, Inc. Common Stock
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap1.88B
P/E RatioN/A
Dividend YieldN/A
Beta1.187
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
1200,000 shares
$892k
0
6-9months
9858,670 shares
$4.0M
0
9-12months
2310,125 shares
$1.2M
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.